GEOVAX LABS INC Share Price Today: Live Updates & Key Insights

GEOVAX LABS INC share price today is $1.46, up 2.8%. The stock opened at $1.4601 against the previous close of $1.43, with an intraday high of $1.48 and low of $1.33.

GEOVAX LABS INC Share Price Chart

GEOVAX LABS INC

us-stock
To Invest in {{usstockname}}
us-stock

GEOVAX LABS INC Share Price Performance

$1.46 0.028(2.8%) GOVX at 23 Mar 2026 01:21 PM Biotechnology
Lowest Today 1.33
Highest Today 1.48
Today’s Open 1.4601
Prev. Close 1.43
52 Week High 35.25
52 Week Low 1.26
Day’s Range: Low 1.33 High 1.48
52-Week Range: Low 1.26 High 35.25
1 day return -
1 Week return -15.02
1 month return -7.54
3 month return +775.52
6 month return +119.43
1 year return +5.37
3 year return -86.27
5 year return -98.13
10 year return -

GEOVAX LABS INC Institutional Holdings

Citadel Advisors Llc 1.11

Renaissance Technologies Corp 1.09

Vanguard Group Inc 0.44

Geode Capital Management, LLC 0.37

Fidelity Extended Market Index 0.25

Vanguard Institutional Extnd Mkt Idx Tr 0.21

NT Ext Equity Mkt Idx Fd - L 0.11

UBS Group AG 0.11

BlackRock Inc 0.05

Morgan Stanley - Brokerage Accounts 0.05

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.05

Spartan Extended Market Index Pool F 0.04

Fidelity Series Total Market Index 0.04

State Street Corp 0.03

Scientech Research LLC 0.03

Fidelity Total Market Index 0.03

Northern Trust Corp 0.02

Northern Trust Extended Eq Market Idx 0.02

Citigroup Inc 0.02

Spartan Total Market Index Pool G 0.02

Blackrock Extended Mkt Fund CF 0.01

Extended Equity Market Fund K 0.01

Advisor Group Holdings, Inc. 0.01

SBI Securities Co Ltd 0.01

NT Ext Equity Mkt Idx Fd - NL 0.00

Moneta Group Investment Advisors Inc 0.00

Bank of America Corp 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Extended Equity Market Fund M 0.00

SSgA U.S. Total Market Index Strategy 0.00

Wells Fargo & Co 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

HARBOUR INVESTMENTS, INC. 0.00

Quaker Wealth Management, LLC 0.00

Royal Bank of Canada 0.00

Tower Research Capital LLC 0.00

GEOVAX LABS INC Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

GEOVAX LABS INC Fundamentals

Market Cap 3.27 M

PB Ratio 0.6616

PE Ratio 0.0

Enterprise Value 1.83 M

Total Assets 8.16 M

Volume 147801

GEOVAX LABS INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:81000 0.1M, FY21:385000 0.4M, FY20:1823000 1.8M, FY19:1175896 1.2M

Annual Profit FY23:null 0.0M, FY22:81000 0.1M, FY21:385000 0.4M, FY20:1823000 1.8M, FY19:1175896 1.2M

Annual Net worth FY23:null 0.0M, FY22:-14014561 -14.0M, FY21:-18531479 -18.5M, FY20:-2938344 -2.9M, FY19:-2375124 -2.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:852282 0.9M, Q1/2025:1636863 1.6M, Q3/2024:2789484 2.8M, Q2/2024:300677 0.3M

Quarterly Profit Q3/2025:-16802 -0.0M, Q2/2025:852282 0.9M, Q1/2025:1619942 1.6M, Q3/2024:2789484 2.8M, Q2/2024:-3976191 -4.0M

Quarterly Net worth Q3/2025:-6318914 -6.3M, Q2/2025:-5369783 -5.4M, Q1/2025:-5357651 -5.4M, Q3/2024:-5815468 -5.8M, Q2/2024:-5064042 -5.1M

About GEOVAX LABS INC & investment objective

Company Information GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Mr. David Alan Dodd

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

GEOVAX LABS INC FAQs

What is the share price of GEOVAX LABS INC today?

The current share price of GEOVAX LABS INC is $1.46.

Can I buy GEOVAX LABS INC shares in India?

Yes, Indian investors can buy GEOVAX LABS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy GEOVAX LABS INC shares in India?

You can easily invest in GEOVAX LABS INC shares from India by:

Can I buy fractional shares of GEOVAX LABS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of GEOVAX LABS INC?

GEOVAX LABS INC has a market cap of $3.27 M.

In which sector does GEOVAX LABS INC belong?

GEOVAX LABS INC operates in the Biotechnology sector.

What documents are required to invest in GEOVAX LABS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of GEOVAX LABS INC?

The PE ratio of GEOVAX LABS INC is N/A and the PB ratio is 0.66.